Simple Summary Beyond mutations, epigenetic changes have been described as drivers for
cancer as well. While leaving the overall DNA structure intact, they can be responsible for …

Histone deacetylases (HDACs) play an important role in regulating the expression of genes
involved in tumorigenesis and tumor maintenance, and hence they have been considered …

Abstract Background Histone deacetylases (HDACs) are one of the essential epigenetic
targets in cancer treatment. These enzymes play key roles in post-translation modification …

Inducing protein degradation by proteolysis targeting chimera (PROTAC) has provided great
opportunities for scientific research and industrial applications. Histone deacetylase (HDAC) …

Introduction The current drug discovery paradigm of 'one drug, multiple targets' has gained
attention from both the academic medicinal chemistry community and the pharmaceutical …

Abstract Neurofibromatosis Type 2 (NF2) is a rare tumor disorder caused by pathogenic
variants of the merlin tumor suppressor encoded by NF2. Patients develop vestibular …

Inhibition of PI3K and histone deacetylase (HDAC) activity simultaneously using a single
molecule appears to be a promising approach for cancer treatment. Current PI3K/HDAC …

Designing and discovering compounds for dual-target inhibitors is challenging to synthesize
new, safer, and more efficient drugs than single-target drugs, especially to treat multifactorial …

Background: Neurological disorders are composed of several diseases that affect the central
and peripheral nervous system; among these are neurodegenerative diseases, which lead …

Histone deacetylases (HDACs) and lysine-specific demethylase 1 (LSD1) are attractive
targets for epigenetic cancer therapy. There is an intimate interplay between the two …